| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgery (CRF, MSB, DGC), Epidemiology and Biostatistics (KSP), and Pathology (KB), Memorial Sloan-Kettering Cancer Center, New York, New York.
Correspondence: Address correspondence and reprint requests to: Daniel G. Coit, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021; Fax: 212-717-3400; E-mail: coitd{at}mskcc.org
Background: The overall prognosis of patients with thick cutaneous melanoma (TCM) is generally thought to be poor. Surgically staging these patients with sentinel lymph node (SLN) biopsy remains controversial. This study was performed to determine whether SLN status improved our ability to predict outcome over other known prognostic factors and to develop a model incorporating independent prognostic factors to estimate the risk of recurrence for an individual patient.
Methods: A prospective database identified patients with TCM (>4.0 mm or Clark level V) and clinically negative nodes who underwent SLN biopsy. Univariate and multivariate analyses were performed.
Results: From 1991 to 2001, 126 patients were identified; 75 (60%) were male. The median age was 60 years. The median tumor thickness was 5.5 mm, and 43% were ulcerated. Thirty percent of patients had a positive SLN. Recurrence was seen in 50 patients (40%). Median follow-up, relapse-free survival, and overall survival were 25, 50, and 68 months, respectively. Factors independently predictive of recurrence were age 
60 years, depth >5.5 mm, ulceration, and SLN positivity. SLN status was the most significant prognostic factor (P < .001). The relative risk of recurrence for an individual patient ranged from 1 in patients for whom no adverse factors were present to 29.4 when all factors were present.
Conclusions: SLN status was the strongest independent predictor of outcome in patients with TCM. However, patients with TCM are prognostically heterogeneous, and all independently predictive factors should be considered when an individual patient’s risk of recurrence is assessed.
Key Words: Thick cutaneous melanoma • Sentinel lymph node • Prognostic model—Recurrence
This article has been cited by other articles:
 |
|
 |
|
  C. Caraco, U. Marone, E. Celentano, G. Botti, and N. Mozzillo Impact of False-Negative Sentinel Lymph Node Biopsy on Survival in Patients with Cutaneous Melanoma Ann. Surg. Oncol., September 1, 2007; 14(9): 2662 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al. Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Ross Early-stage melanoma: staging criteria and prognostic modeling. Clin. Cancer Res., April 1, 2006; 12(7): 2312s - 2319s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Uren Sentinel Lymph Node Biopsy in Melanoma J. Nucl. Med., February 1, 2006; 47(2): 191 - 195. [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Cormier, Y. Xing, M. Ding, J. E. Lee, P. F. Mansfield, J. E. Gershenwald, M. I. Ross, and X. L. Du Population-Based Assessment of Surgical Treatment Trends for Patients With Melanoma in the Era of Sentinel Lymph Node Biopsy J. Clin. Oncol., September 1, 2005; 23(25): 6054 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Eigentler, P. G. Buettner, U. Leiter, and C. Garbe Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry J. Clin. Oncol., November 1, 2004; 22(21): 4376 - 4383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, and J. E. Gershenwald Lymphatic Mapping in the Molecular Era Ann. Surg. Oncol., April 1, 2004; 11(4): 362 - 374. [Full Text] [PDF]
|
|
|
|
|
|
C. Caraco, E. Celentano, S. Lastoria, G. Botti, P. A. Ascierto, and N. Mozzillo Sentinel Lymph Node Biopsy Does not Change Melanoma-Specific Survival Among Patients with Breslow Thickness Greater than Four Millimeters Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 198S - 202S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Busam Advances in Molecular Staging of Melanoma Patients: Multimarker Analysis of Archival Lymph Node Tissue J. Clin. Oncol., October 1, 2003; 21(19): 3550 - 3551. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Estourgie, O. E. Nieweg, R. A. Valdes Olmos, C. A. Hoefnagel, and B. B. R. Kroon Review and Evaluation of Sentinel Node Procedures in 250 Melanoma Patients With a Median Follow-Up of 6 Years Ann. Surg. Oncol., July 1, 2003; 10(6): 681 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Carlson, D. R. Murray, A. Hestley, C. A. Staley, R. H. Lyles, and C. Cohen Sentinel Lymph Node Mapping for Thick (>=4-mm) Melanoma: Should We Be Doing It? Ann. Surg. Oncol., May 1, 2003; 10(4): 408 - 415. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
